TCM
CBIO

Tang Capital Management’s Crescent Biopharma CBIO Stock Holding History

Tang Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9M Hold
1,160,000
– – 0.95% 24
2026
Q1 		$21.3M Buy
1,160,000
+287,602
+33% +$3.3M 1.08% 24
2025
Q4 		$10.3M Buy
872,398
+192,574
+28% +$2.45M 0.51% 39
2025
Q3 		$8.08M Buy
679,824
+629,672
+1,256% +$8.35M 0.31% 71
2025
Q2 		$809K Buy
+50,152
New +$1.06M 0.04% 170

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Tang Capital Management's CBIO Position: Q2 2026 in Review

Tang Capital Management held its Crescent Biopharma (CBIO) position steady in Q2 2026 at 1,160,000 shares worth $20.9M. The position accounts for 0.95% of the portfolio, ranked #24.

Tang Capital Management first reported a position in CBIO in Q2 2025 and has held it in 5 quarters since. The position peaked at $21.3M in Q1 2026. 82 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • Tang Capital Management held 1,160,000 shares of Crescent Biopharma worth $20.9M as of Q2 2026.
  • Tang Capital Management left its Crescent Biopharma share count unchanged in Q2 2026.
  • Crescent Biopharma made up 0.95% of Tang Capital Management's portfolio in Q2 2026, its #24 holding.
  • Tang Capital Management first reported a position in Crescent Biopharma in Q2 2025 and has held it in 5 quarters since.
  • Tang Capital Management's Crescent Biopharma position peaked at $21.3M in Q1 2026.
  • 82 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Tang Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.